CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
February 2017—WaveSense introduced its nRichDX system for the bulk isolation of target cells and nucleic acids from liquid biopsies. The nRichDX uses the company’s proprietary paramagnetic bead technology to enable the capture of circulating tumor cells and cell-free DNA or cell-free RNA in quantities sufficient for analysis by next-generation sequencing and PCR techniques. The system can capture cells and nucleic acids from an array of sample types, including blood, urine, and bone marrow, and is specifically designed and optimized for high-volume, low-yield specimens. The system is positioned to complement the company’s EpiSep direct-to-slide enrichment technology.
WaveSense, 949-341-1980